Alembic Pharma Receives FDA Approval for Generic Ophthalmic Solution, Estimated Market Size at $61 Million
AI Summary1 min read
TL;DR
Alembic Pharmaceuticals has secured FDA approval for a generic version of Travoprost Ophthalmic Solution, used to treat glaucoma and ocular hypertension, with an estimated market value of $61 million through September 2025.
Alembic Pharmaceuticals has received FDA approval for its generic Travoprost Ophthalmic Solution, equivalent to Sandoz's Travatan Z. The solution is used to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The product has an estimated market size of $61 million for the twelve months ending September 2025.
